Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib plus chemotherapy in ALK-positive resectable non-small cell lung cancer
NL-OMON59287Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of alectinib, pemetrexed, cisplatin and carboplatin in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Roche. Primary endpoints: Incidence, type, and severity of adverse events and Investigator-assessed pathologic complete response. Started Mar 2025; status: completed.
02
Drugs
alectinibpemetrexedcisplatincarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59287.